Drug intelligence / Profile preview

S 33138

Development stage: Discontinued
Lead developer: Servier
Modality: Small Molecules
Administration: Oral

Overview

S 33138 is an investigational small molecule antipsychotic developed by Servier for the treatment of schizophrenia. It functions as a preferential dopamine D3 receptor antagonist, while also exhibiting antagonist activity at dopamine D2, serotonin 5-HT2A, and 5-HT2C receptors. This multi-receptor profile was intended to provide efficacy against both positive and negative symptoms of schizophrenia with a reduced risk of extrapyramidal side effects compared to standard D2-focused antipsychotics. The compound reached Phase IIb clinical trials, including studies comparing it to olanzapine and risperidone, but development has since been discontinued.

Targets

HTR2A (Serotonin receptor 5-HT2A)DRD3 (Dopamine receptor D3)HTR2C (5-hydroxytryptamine 2C receptor)DRD2 (Dopamine D2 Receptor)

Beyond the preview

Go deeper on S 33138.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on S 33138.

Explore the full profile